An evidence base that includes more high-quality studies on heterogeneity in the comparative effectiveness of SGLT2i, GLP1-RA, and other drug classes is needed to advance the field towards clinically useful precision diabetes medicine. The gene discussed is GLP1R; the disease is diabetes mellitus.